What is Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization?

Sarepta Therapeutics, Inc. (SRPT) reported cost of goods sold excluding amortization of $137.56M in Q1 2025.

How has Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization changed year-over-year?

Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization increased by 172.1% year-over-year, from $50.56M to $137.56M.

Discontinued — last reported Q1 '25

All Other Segments$108.77M-20.9%

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Market cap$1.76B-63.1%

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept srpt:CostOfGoodsSoldExcludingAmortization.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2025, on SEC EDGAR. View the filing →

What is Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization?: Sarepta Therapeutics, Inc. (SRPT) reported cost of goods sold excluding amortization of $137.56M in Q1 2025.
How has Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization changed year-over-year?: Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization increased by 172.1% year-over-year, from $50.56M to $137.56M.